First Wave Bio Inc. (FWBI) has disclosed a new risk, in the Supply Chain category.
First Wave Bio Inc. faces significant uncertainty regarding the completion of the Niclosamide Sale as outlined in their Letter of Intent (LOI) dated December 27, 2023. Despite the initial agreement, changes in the deal’s structure and amount due to negotiations or due diligence could lead to different outcomes. The approval process, involving the company’s Board and various closing conditions, presents further hurdles. Should the sale fall through, not only would incurred expenses yield no return for shareholders, but there could also be materially adverse effects on First Wave Bio Inc.’s stock price and financial health.
The average FWBI stock price target is $36.00, implying 721.92% upside potential.
To learn more about First Wave Bio Inc.’s risk factors, click here.
